Home Companies Catalysts Deep Dives
Tezspire tezepelumab APPROVED
Drug Profile
ModalityAntibody
RouteSC
Therapy AreaR&I
Launch2021-12-17
US LOE2034-12-17
Peak Sales Est$4000M
Formulations[{"id":"tezspire-sc","doses":"210mg","route":"SC","device":"Pre-filled syringe/autoinjector","settin
Companies
AMGN (CO_DEVELOPER)50%
AZN (ORIGINATOR)50%
Mechanism: TSLP inhibitor
Expert: Human IgG2λ monoclonal antibody that blocks TSLP interaction with its receptor, inhibiting multiple downstream inflammatory pathways independent of phenotype.
Everyday: Blocks a protein that triggers the allergic inflammation cascade at its source.
Targets: ["TSLP"]
Revenue History
PeriodRevenue ($M)
2023$502M
2024$972M
2025$1,478M
Q4 2024$296M
Q4 2025$474M
Programs (2)
IndicationStageKey StudyRegional Status
COPD (type 2/inflammatory)PHASE3COURSE[]
Severe asthmaAPPROVEDNAVIGATOR[{"stage":"APPROVED","region":"US","approval_date":"2021-12-17"},{"stage":"APPRO
Upcoming Catalysts (2)
Tezspire - EoE - Ph3 - Topline H2 2026
Tezspire - COPD - Ph3 Data H2 2026
Notes
+52% YoY. Co-developed with AZN (50/50). CRSwNP positive (WAYPOINT) — filing imminent. COPD and EoE Ph3 data in 2026. Breakthrough therapy designation for COPD. Could become $4B+ drug across asthma, CRSwNP, COPD, EoE.
Data from Supabase · Updated 2026-03-24